NETWORK ID: CN10441 | 

STAT3 transcriptional regulatory sub-network

EXPERIMENTS
condition PF-05212384
condition dose 2.5 uM
condition time 4 h
CELL LINE OCILY19
CONDITION DETALIS
ID BRD-K07955840
name PF-05212384
type trt_cp; compound
molecular formula C32H41N9O4
molecular weight 615.7 g/mol
smiles
CN(C)C1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6
clinical phase
Phase 3

Differential expressed genes in this transcriptional regulatory sub-network

If you want to view heatmap, you can click [expand]

You can download all DEGs data.

Symbolcontrolcontrolcontrolconditionconditioncondition
ACTN110.529110.02629.54738.70549.06658.6828
ATP2A39.3059.08638.99678.23488.31247.9058
ATP6V0B8.22217.70038.03826.96536.9877.2396
BYSL10.498610.230610.39849.71969.42959.3145
CDKN1A9.11238.19478.85936.62546.74257.0143
CHI3L28.40078.03647.22185.59956.26786.5756
DBN15.65885.94046.1664.72885.12594.7124
EMP39.30158.50358.85817.38017.69337.597
ENO27.12137.01436.98755.98685.64646.2783
FARSA8.98138.93419.39158.36318.39588.245
FUT76.50456.34896.33545.64215.72885.8352
SFN5.26824.98525.15524.33024.40884.5114
GPI11.489711.29311.516110.766410.116810.1625
HMGCR9.05618.94649.22278.48698.19088.0801
HMGCS113.54613.86513.670211.664411.543311.649
DNAJA111.179810.813511.0739.69479.278610.3804
HSPA811.192411.225411.02359.05038.92338.8032
DNAJB18.29567.60787.98846.25386.44676.8196
IDI112.19811.697911.137910.082610.501810.2535
IMPDH19.01118.7148.9088.12598.22188.3934
INPP5A4.59223.9614.74873.18213.49633.2957
MAT2A12.472712.472712.446911.586811.230611.588
NMB8.18167.51567.6086.77266.72236.66
NOP211.867111.479111.592311.035710.41910.781
ODC111.726211.043611.750910.23459.479610.2421
PDGFA6.32355.98127.10374.94844.93455.3465
PFAS11.865311.867112.186810.988311.079511.4576
PLAGL28.2348.2058.52017.74367.26857.3103
PTPN611.801513.118811.70119.75349.66499.8137
PTPRCAP10.4259.911710.3138.41638.86249.1735
SLC1A510.01099.65969.09568.46248.54078.5317
SNRPF13.43913.542513.585912.578312.828813.0682
SOX48.37358.80328.62136.58137.45567.2148
SRP729.28318.90828.90398.23648.40398.2779
STAT5A6.15885.52365.71364.63054.75595.0701
TDG12.695912.032212.302711.213411.111.2517
PRDX28.59897.93348.30847.02526.64026.7579
TTC48.94619.14729.29418.48338.36018.5718
UQCRFS111.687711.863811.658210.890710.880410.9848
MANF8.25867.99958.03467.60076.92646.9843
EIF2B47.99327.90048.07517.07037.30427.4025
KIF3B7.98587.91417.80496.85277.19777.3905
BAG59.60659.56589.47648.77368.75918.8682
ACAP18.1888.09478.35197.26177.47727.597
TATDN27.49577.23137.50496.66426.53916.8884
SCO210.604510.498610.70329.92429.47889.8054
PPIF10.733210.102910.54779.65818.36128.6649
TRIM2812.192512.046611.965710.862811.407211.396
ZMPSTE2410.61910.612810.79089.852810.14769.9113
TMEM14712.029612.058511.431110.927810.818310.6297
CHERP9.42239.58559.97888.36988.58468.9331
PWP112.04212.002812.16611.341411.458311.4893
PDCD118.64348.40378.49987.89487.63327.6328
SPEN9.34019.53289.41648.33958.23558.3119
RRP1B10.393710.658510.76878.51339.24378.9962
PPRC110.58859.977510.47629.17748.86169.6341
JMJD612.069311.921312.008210.684610.570510.5526
NUP6210.730410.766810.30619.35049.2919.9333
TMEM979.63869.64549.77317.91448.35838.8501
DNTTIP211.863812.16612.203610.525410.813511.1379
GEMIN49.24149.44918.86248.07728.14418.1997
RRP1511.748811.848611.561310.606111.016310.8628
ZNF59312.46912.46912.613911.937511.858911.6948
POLR1D12.724512.532612.500411.76911.937511.7151
GAL10.811210.996710.766810.009610.243910.2888
MRTO411.554611.552911.907910.727810.797610.5366
SS18L210.27910.069510.46479.45599.45089.7576
TNFRSF12A7.4387.74277.46146.6997.00146.5823
NOP1613.332513.481713.566411.880211.661311.9251
TRIAP111.759611.484212.193610.558510.535610.8893
SRRT12.144512.144512.07611.299711.5711.6079
RHOF7.7328.1877.70246.79397.17567.0469
EXOSC46.00625.95575.86994.19914.84053.666
PUS712.017711.933511.951410.872910.463111.0725
YTHDF16.83166.99297.07985.88396.15956.201
ATAD3A8.21848.13528.44877.69357.5177.5762
FBXW78.07728.04098.0366.97277.1917.6022
BATF38.938.92379.28318.06048.10048.15
SLC39A45.8145.38725.1724.39684.01794.2138
ZMIZ110.947511.403910.17589.28989.53599.6769
BAHCC16.05256.03916.2015.27955.25835.5383
ZNF5747.84767.86877.45236.90636.896.9212
AEN8.61158.49318.61337.82497.44857.6391
TMEM10910.446610.360610.37429.53389.43079.7033
DCTPP111.675111.374111.249110.637310.724810.5761
CCDC8611.225411.280211.168410.157210.24319.7565
SLC52A27.39657.32787.32316.70966.53136.4365
GALNT147.57548.04948.41635.95987.01216.3915
NLRX16.67096.45336.64255.82346.11155.969
ZNF6727.66877.69737.75417.03827.04166.9949
SLC35E16.98137.03037.24876.17746.43456.1574
TSEN28.94118.99398.96588.19268.26268.1367
FTSJ39.09169.13979.41778.41328.2098.47
MSL18.43658.53178.20287.61757.34367.7682
SRRD8.49788.69538.75917.9048.03957.9377

STAT3 transcriptional regulatory sub-network

The possible genes regulated by the transcription factor were obtained by calculation, and the results were displayed in the form of network

More information of [PF-05212384] and [STAT3]. Click to[expand]

Curated target protein/gene of this condition/drug

Protein target or gene target of this condition curated by previous studies and their associated KEGG pathways are shown below

Target Gene Protein Amino acids More

MTOR
Serine/threonine-protein kinase mTOR
2549
Uniport KEGGpathway

ARTICLE: PF-05212384

[1] A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.

[2] Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.

[3] Bioanalysis of Targeted Nanoparticles in Monkey Plasma via LC-MS/MS.

[4] First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

[5] Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.

[6] A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.

[7] Structural Aspects of mTOR Inhibitors: Search for Potential Compounds.

[8] Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX.

TRANSCRIPTION FACTOR: STAT3

Gene Protein Amino acids More

STAT3
Signal transducer and activator of transcription 3
770
Uniport KEGGpathway